Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Talicabtagene autoleucel |
| Trade Name | |
| Synonyms | Tali-cel|HCAR19|HCAR-19 |
| Drug Descriptions |
Talicabtagene autoleucel comprises T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CD19 and contains a 4-1BB (TNFRSF9) costimulatory domain, which potentially inhibit growth of CD19-expressing tumors (PMID: 40274761). |
| DrugClasses | CD19 Immune Cell Therapy 76 |
| CAS Registry Number | NA |
| NCIT ID | C215774 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Talicabtagene autoleucel | Talicabtagene autoleucel | 0 | 1 |